Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Nordic Nanovector ASA ( (DE:8NN) ).
Thor Medical ASA has successfully registered a share capital increase following a subsequent offering, which resulted in the allocation and issuance of over 10.5 million new shares. This move, now authorized by the Norwegian Register of Business Enterprises, increases the company’s share capital to NOK 62,881,704.20, divided into more than 314 million shares, each carrying one vote at the general meeting. This development reinforces Thor Medical’s financial base and potentially strengthens its market positioning in the radiopharmaceutical industry.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier of radionuclides, primarily focusing on alpha particle emitters derived from naturally occurring thorium. The company utilizes a proprietary production process that does not require irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway, and is publicly traded on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
YTD Price Performance: -4.09%
Average Trading Volume: 5,580
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €65.57M
For detailed information about 8NN stock, go to TipRanks’ Stock Analysis page.
